Wave Life Sciences (WVE) investor relations material

Executive summary

• Proposal to redomicile the parent company from Singapore to Delaware via a Scheme of Arrangement, exchanging each Singapore share for a Delaware share on a one-for-one basis.

• The board unanimously recommends the transaction, citing alignment with operational footprint, administrative efficiencies, and reduced compliance costs.

• The transaction will not affect day-to-day operations, Nasdaq listing, or SEC reporting; shares will continue to trade under the same symbol.

• The transaction is expected to be tax-free for most U.S. shareholders, but holders are advised to consult tax advisors due to complex international tax implications.

• The effective date is subject to shareholder and Singapore Court approval, with a long-stop date of December 31, 2026.

Voting matters and shareholder proposals

• Shareholders are asked to approve the Scheme of Arrangement at a special meeting convened by court order.

• Approval requires a majority in number and at least 75% in value of shares present and voting.

• DTC participants may split votes; non-DTC participants must vote all shares the same way.

• No appraisal or dissenters' rights are available under Singapore law.

• Shareholder proposals for future meetings must comply with both SEC and Singapore Companies Act requirements.

Board of directors and corporate governance

• The current board and executive officers will continue in their roles post-transaction.

• Delaware law will govern board structure, director elections, and removal; directors will be elected annually by plurality vote.

• Anti-takeover provisions under Delaware law, including Section 203, will apply.

• Advance notice and supermajority requirements for certain amendments are included in the new governing documents.